Dyne Therapeutics, Inc. (DYN) Cash Flow Statement
Dyne Therapeutics, Inc. (DYN) generated -$477.8M of operating cash flow over the twelve months to 2026-06-30, spent $21.4M on capital expenditure and had free cash flow of -$499.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DYNDyne Therapeutics, Inc.Follow DYN — free
—
Price chart with a free account
- Market cap
- 2.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.05 | -0.12 | -0.15 | -0.19 | -0.29 | -0.40 | -0.48 | |
| Capital expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | -0.02 | |
| Free cash flow | -0.05 | -0.12 | -0.16 | -0.19 | -0.29 | -0.42 | -0.50 | |
| Stock-based compensation | 0.01 | 0.02 | 0.02 | 0.02 | 0.05 | 0.05 | — |
USD billions · SEC XBRL
Dyne Therapeutics, Inc. — questions
- What is Dyne Therapeutics, Inc.'s operating cash flow?
- -$477.8M over the twelve months to 2026-06-30.
- How much does Dyne Therapeutics, Inc. spend on capital expenditure?
- $21.4M over the twelve months to 2026-06-30.
- What is Dyne Therapeutics, Inc.'s free cash flow?
- -$499.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Dyne Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.